Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET–CT-documented First Remission

Glober, Gordon; Gunther, Jillian R.; Fang, Penny; Milgrom, Sarah A.; Korivi, Brinda Rao; Jensen, Corey T.; Wagner‐Bartak, Nicolaus A.; Ahmed, Sairah; Lee, Hun Ju; Nair, Ranjit; Steiner, Raphaël; Parmar, Simrit; Iyer, Swaminathan P.; Westin, Jason R.; Fayad, Luis; Rodriguez, Maria Alma; Neelapu, Sattva S.; Nastoupil, Loretta J.; Flowers, Christopher R.; Dabaja, Bouthaina S.; Pinnix, Chelsea C.

doi:10.1016/j.clml.2020.02.008

Cited by 3 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study including 78 patients with localized-stage classical HL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine, the relapse rate for this group was very low and they found 11 cases of false positives, concluding that elimination of surveillance imaging could reduce healthcare expenses and cumulative radiation doses [ 18 ]. Another recent study, which included 179 patients with classical HL at all stages who reached CR at the end of first-line treatment, identified that only 5% of the patients relapsed, for whom 463 scans were performed per relapse detected in the two-year post-therapy surveillance [ 19 ]. Likewise, hypothetical cost-benefit analyses have demonstrated CT follow-up to be of minimal survival benefit for patients at all stages of disease and to be associated with a reduction in quality-adjusted life expectancy for those with early-stage disease [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment

Oreiro

Martín

Gomez

et al. 2021

Cancers

View full text Add to dashboard Cite

The optimal strategy for early surveillance after first complete response is unclear in Hodgkin lymphoma. Thus, we compared the various follow-up strategies in a multicenter study. All the included patients had a negative positron emission tomography/computed tomography at the end of induction therapy. From January 2007 to January 2018, we recruited 640 patients from 15 centers in Spain. Comparing the groups in which serial imaging were performed, the clinical/analytical follow-up group was exposed to significantly fewer imaging tests and less radiation. With a median follow-up of 127 months, progression-free survival at 60 months of the entire series was 88% and the overall survival was 97%. No significant differences in survival or progression-free survival were found among the various surveillance strategies. This study suggests that follow-up approaches with imaging in Hodgkin lymphoma provide no benefits for patient survival, and we believe that clinical/analytical surveillance for this group of patients could be the best course of action.

show abstract

Section: Discussionmentioning

confidence: 99%

SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment

Oreiro

Martín

Gomez

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…As expected, this mode of surveillance was not cost-effective, totaling USD 296,817. The MD Anderson's retrospective experience regarding early HL (n = 179) showed that only 0.2% of relapses were detected by routine surveillance, with 463 scans needed to detect one relapse [24]. Lee at al.…”

Section: How To Detect the Relapse Of Hodgkin Lymphomamentioning

confidence: 99%

How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?

Milunović

2024

Medicina

View full text Add to dashboard Cite

Hodgkin lymphoma is characterized by a high cure rate in the modern era of medicine regardless of stage, but patients suffer from a high risk of comorbidity associated with the administered therapy. The main aim of this review article is to assess and analyze the various comorbidities associated with Hodgkin lymphoma and address the survivorship of patients, including fertility, secondary cancers due to cardiovascular toxicity, and quality of life. Furthermore, this review explores the optimal strategy for detecting relapse. The treatment paradigm of Hodgkin lymphoma has shifted, with a paradigm shift toward achieving a high cure rate and low toxicity as a standard of care in this patient population. Checkpoint inhibitors, especially nivolumab, in combination with chemotherapy are increasingly being studied in the first line of therapy. However, their long-term toxicity remains to be assessed in longer follow-up. In conclusion, Hodgkin lymphoma survivors, regardless of their treatment, should be followed up individually by a multidisciplinary survivorship team in order to detect and properly treat the long-term side effects of therapy.

show abstract